Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: Might c-kit represent a therapeutic target?

Veterinary Immunology and Immunopathology

Volumn 154, Issue 3-4, 2013, Pages 153-159

  Giantin, M ^a   Aresu, L ^a   Arico A ^a   Gelain, M E ^a   Riondato, F ^b   Comazzi, S ^c   Dacasto, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

B cell lymphoma; C kit, Dog; T cell lymphoma; Tyrosine kinase inhibitors

Indexed keywords

COMPLEMENTARY DNA; TYROSINE KINASE RECEPTOR;

ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANINE LYMPHOMA; CONTROLLED STUDY; DNA SEQUENCE; DOG; DOG DISEASE; EXON; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; LIMIT OF QUANTITATION; LYMPH NODE BIOPSY; NONHUMAN; ONCOGENE C KIT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA;

ANIMALS; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER;

CANIS FAMILIARIS;

EID: 84880133783     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.05.014     Document Type: Article

References (40)

1. Adam F., Villiers E., Watson S., Coyne K., Blackwood L. Clinical pathological and epidemiological assessment of morphologically and immunologically confirmed canine leukaemia. Vet. Comp. Oncol. 2009, 7(3):181-195.
2. Advani A.S. Targeting the c-kit receptor in the treatment of acute myelogenous leucemia. Curr. Hematol. Malig. Rep. 2006, 1:101-107.
3. Advani A.S., Rodriguez C., Jin T., Jawde R.A., Saber W., Baz R., Kalaycio M., Sobecks R., Sekeres M., Tripp B., His E. Increased c-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk. Res. 2008, 32:913-918.
4. Aldinucci D., Poletto D., Nanni P., Degan M., Gloghini A., Di Francia R., Russo S., Carbone A., Pinto A., Gattei V. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br. J. Haematol. 2002, 118:1055-1064.
5. Aricò A., Giantin M., Gelain M.E., Riondato F., Comazzi S., Rϋtgen B.C., Essler S.E., Dacasto M., Castagnaro M., Aresu L. The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study. BMC Vet Res 2013, 9:94.
6. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., Nadali G., Grillo G., Haas O.A., Biondi A., Morra E., Larizza L. KIT activating mutations: incidence in adult and pediatric acute myeloid leucemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
7. Bravo P., Diaz Agustin B., Belias C., Gonzalez D., Camara C., Fernandez Fuertes I., Almeida J., Garcia Sanz R., Orfao A., Escribano L. Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation. Am. J. Hematol. 2000, 63(4):226-229.
8. Breen M., Modiano J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Res. 2008, 16(1):145-154.
9. Chen J., Yanuch R.R.III, Abbondanzo S.L., Chu W.S., Aguilera N.S. c-Kit (CD117) reactivity in extramedullary myeloid tumor/granulocytic sarcoma. Arch. Pathol. Lab. Med. 2001, 125:1448-1452.
10. Dunmire V., Wu C., Symmans W.F., Zhang W. Increased yield of total RNA from fine-needle aspirates for use in expression microarray analysis. Biotechniques 2002, 33(4). 890-2, 894, 896.
11. Edling C.E., Hallberg B. c-KIT - a hematopoietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol. 2007, 39:1995-1998.
12. Escribano L., Ocqueteau M., Almeida J., Orfao A., San Miguel J.F. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk. Lymphoma 1998, 30:459-466.
13. Fournel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., Bryon P.A., Felman P. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J. Comp. Pathol. 1997, 117:35-59.
14. Giantin M., Aresu L., Aricò A., Gelain M.E., Riondato F., Martini V., Comazzi S., Dacasto M. Evaluation of tyrosine-kinase c-KIT receptor (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target?. Vet. Immunol. Immunopathol. 2012, 152(3-4):325-332.
15. Giantin M., Vascellari M., Morello E.M., Capello K., Vercelli A., Granato A., Lopparelli R.M., Nassuato C., Carminato A., Martano M., Mulinelli F., Da casto M. c-KIT messanger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. J. Vet. Diagn. Invest. 2012, 24(1):116-126.
16. Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A.H., Hählen K., Reinhardt D., Creutzig U., Kaspers G.J., Heinrich M.C. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
17. Hongyo T., Li T., Syaifudin M., Baskar R., Ikeda H., Kanakura Y., Aozasa K., Nomura T. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 2000, 60:2345-2347.
18. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J. Vet. Intern. Med. 2008, 22:985-988.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-δδCt method. Methods 2001, 25:402-408.
20. London C.A. Tyrosine kinase inhibitors in veterinary medicine. Top. Companion Anim. Med. 2009, 24(3):106-112.
21. London C.A., Hannah A.L., Zadovoskaya R., Chien M.B., Kollias-Baker C., Rosenberg M., Downing S., Post G., Boucher J., Shenoy N., Mendel D.B., McMahon G., Cherrington J.M. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin. Cancer Res. 2003, 9:2755-2768.
22. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 2009, 15:3856-3865.
23. Lyman S.D., Jacobsen S.E.W. C-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91:1101-1134.
24. Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. Vet. J. 2011, 188:34-38.
25. Marconato L., Gelain M.E., Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol. Oncol. 2012, 31(1):1-9.
26. Nakatsuka S., Hongyo T., Syaifudin M., Nomura T., Shingu N., Aozasa K. Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland. Jpn. J. Cancer Res. 2002, 93(3):267-274.
27. Natkunam Y., Rouse R.V. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. Am. J. Surg. Pathol. 2000, 24:81-91.
28. Ocqueteau M., Orfao A., Garcia-Sanz R., Almeida J., Gonzalez M., San Miguel J.F. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br. J. Haematol. 1996, 95:489-493.
29. Ozaki K., Yamagami T., Nomura K., Narama I. T-cell lymphoma with eosinophilic infiltration involving the intestinal tract in 11 dogs. Vet. Pathol. 2006, 43:339-344.
30. Pinto A., Gloghini A., Gattei V., Aldinucci D., Zagonel V., Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood 1994, 83:785-792.
31. Potti M., Ganti A.K., Kargas S., Koch M. Immunohistochemical detection of c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res. 2002, 22(5):2899-2901.
32. Rassidakis G.Z., Georgakis G.V., Oyarzo M., Younes A., Medeiros L.J. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod. Pathol. 2004, 17:946-953.
33. Ray P., Krishnamoorthy N., Ray A. Emerging functions of c-kit and its ligand stem cell factor in dendritic cells. Cell Cycle 2008, 7(18):2826-2832.
34. Shimada A., Taki T., Tabuchi K., Tawa A., Horibe K., Tsuchida M., Hanada R., Tsukimoto I., Hayashi Y. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukaemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006, 107:1806-1809.
35. Shiomitsu K., Bauer R.W., Grasperge B.J., Suter S.E., Waite K.J. Cutaneous epitheliotropic lymphoma with dual CD3 and c-kit expression in a dog. Vet. Clin. Pathol. 2012, 41:594-598.
36. Simon D., Nolte I., Eberle N., Abbrederis N., Killich M., Hirschberger J. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J. Vet. Intern. Med. 2006, 20(4):948-954.
37. Sykora K.W., Tomeczkowski J., Reiter A. C-kit receptors in childhood malignant lymphoblastic cells. Leuk. Lymphoma 1997, 25:201-216.
38. Usher S.G., Radford A.D., Villiers E.J., Blackwood L. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Exp. Hematol. 2009, 37:65-77.
39. Valli V.E., Jacobs R.M., Parodi A.L., Vernau W., Moore P.F. Histological Classification of Haematopoietic Tumors of Domestic Animals, World Health Organization, Second Series, vol III 2002, Armed Forces Institute of Pathology, Washington, DC.
40. Zimpfer A., Went P., Tzankov A., Pehrs A.C., Lugli A., Maurer R., Terracciano L., Pileri S., Dirnhofer S. Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. Histopathology 2004, 45:398-404.